---
title: "《业绩》万成集团股份中期纯利 1,555 万元跌 18%  不派息"
description: "万成集团股份公布 6 月止六个月中期业绩，收益 1.81 亿元，按年增加 1.3%。录得纯利 1,555 万元，倒退 18%，每股盈利 7.75 仙。不派息。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254311660.md"
published_at: "2025-08-24T09:06:27.000Z"
---

# 《业绩》万成集团股份中期纯利 1,555 万元跌 18%  不派息

> 万成集团股份公布 6 月止六个月中期业绩，收益 1.81 亿元，按年增加 1.3%。录得纯利 1,555 万元，倒退 18%，每股盈利 7.75 仙。不派息。

万成集团股份 (01451.HK) 公布 6 月止六个月中期业绩，收益 1.81 亿元，按年增加 1.3%。录得纯利 1,555 万元，倒退 18%，每股盈利 7.75 仙。不派息。

### Related Stocks

- [01451.HK - 万成集团股份](https://longbridge.com/zh-CN/quote/01451.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Huatai Securities Keeps Their Buy Rating on China Literature (CHLLF) | In a report released on February 13, from Huatai Securities maintained a Buy rating on China Literature, with a price ta | [Link](https://longbridge.com/zh-CN/news/275996484.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/276056763.md) |
| Hong Kong’s West Kowloon arts hub secures HK$3 billion, 10-year loan facility | The West Kowloon Cultural District Authority in Hong Kong has secured a HK$3 billion, 10-year loan from ICBC (Asia) to a | [Link](https://longbridge.com/zh-CN/news/275930491.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。